GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gentian Diagnostics AS (OSL:GENT) » Definitions » Stock Based Compensation

Gentian Diagnostics AS (OSL:GENT) Stock Based Compensation : kr2.6 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gentian Diagnostics AS Stock Based Compensation?

Gentian Diagnostics AS's Stock Based Compensation for the three months ended in Dec. 2024 was kr0.1 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was kr2.6 Mil.


Gentian Diagnostics AS Stock Based Compensation Historical Data

The historical data trend for Gentian Diagnostics AS's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gentian Diagnostics AS Stock Based Compensation Chart

Gentian Diagnostics AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.28 4.63 3.35 3.04 2.58

Gentian Diagnostics AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.80 1.25 0.39 0.14

Gentian Diagnostics AS Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.6 Mil.


Gentian Diagnostics AS Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Gentian Diagnostics AS's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Gentian Diagnostics AS Business Description

Traded in Other Exchanges
Address
Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.

Gentian Diagnostics AS Headlines